The clinical effect of paroxetine alone or combined with alprazolam in the treatment of diabetes mellitus with anxiety and depression

Objective: To evaluate the clinical effect of paroxetine alone or combined with alprazolam in the treatment of diabetes mellitus with anxiety and depression. Methods: A total of 66 diabetic patients with anxiety and depression were selected from our hospital from August 2018 to August 2019. The patients were divided into a study group and control group based on the difference in treatment methods, with 33 patients in each group. The control group patients were treated with paroxetine alone, the study group patients were treated with paroxetine and alprazolam, and the clinical effect was compared between the two groups. Results: There was no significant difference in FPG, 2hPG and ACTH between the two groups before treatment (P>0.05). After the treatment, the two groups were significantly lower than before the treatment (P<0.05); after the treatment, the reduction degree of the study group was better than that of the control group, and the difference was statistically significant (P<0.05). The results showed that there was no significant difference between the two groups before and after treatment (P>0.05). After treatment, there was a significant decrease in the two groups compared with before treatment, and the difference was statistically significant (P<0.05). Moreover, after treatment, the research group showed significant improvements compared to the control group (P<0.05). The incidence of adverse reactions was 21.21% in the study group and 36.36% in the control group. Conclusion: The clinical efficacy of paroxetine alone or combined with alprazolam in the treatment of diabetes mellitus with anxiety and depression is better. After treatment, the blood glucose and endocrine level of the patients improved, anxiety and depression symptoms also improved, the incidence of adverse reactions was low, and the safety of use was high.